In this exclusive foundational-level lecture, Dr. Terry Kenakin takes you on a captivating tour through the history of pharmacology: a journey that spans ancient Egypt, revolutionary scientific ideas, Nobel Prize-winning discoveries, and today's digital frontier. But this isn't just about what was—it's about why the past matters now.

Hello GPCR Innovators ,   We’re preparing to launch Terry’s Corner, a new knowledge hub shaped by Dr. Terry Kenakin’s decades of GPCR insight. It will bridge foundational receptor theory with today’s most pressing pharmacological questions, from biased signaling to allosteric design.   Meanwhile, incretin and amylin-based therapies are reshaping the obesity drug landscape. Novo Nordisk’s amycretin showed up to 24% weight loss, CagriSema delivered 22.7% in Phase 3, and semaglu

In his newest lesson, “The Uniqueness of Pharmacology in Drug Discovery,” Terry Kenakin explains why pharmacology isn’t a clean-cut science—it’s a dynamic dialogue between molecule and system.

In this foundational-level lesson, Terry unpacks the real-life process behind discovering new drugs, breaking down the science into accessible, engaging insights for early learners and curious minds.

In the foundational lesson of Terry’s Corner, Dr. Terry Kenakin invites us to challenge outdated assumptions and step into a new era of drug discovery.

Assay development is more than synthesis. Discover how Celtarys is helping scientists solve GPCR research challenges.

Hello GPCR Minds,   This week, you'll learn all about Terry’s Pharmacology Corner, your new learning space focused on GPCR pharmacology. Whether you’re early in your career or pushing the edge of MoA design, weekly lesson help you apply key concepts like binding, signaling, and kinetics in practical, decision-shaping ways. The Corner comes will live monthly AMA sessions with Dr. Kenakin. Get curated content at your own pace.   Subscribe to The Kenakin Brief below to stay in t

Dr. Maria Majellaro shares the pivotal moments that shaped her career, from chemistry tests to launching a biotech company changing GPCR research.

Understanding receptor-ligand interaction is key in drug discovery and biomedical research. Radioligands have been used to study GPCRs...

How Maria Majellaro transitioned from medicinal chemist to biotech CSO, and how Celtarys is now advancing GPCR research tools with Dr. GPCR.

Hello GPCR Trailblazers, This week, we’re spotlighting Celtarys Research, our newest partner, featured in a blog and podcast with CSO Dr. Maria Majellaro, highlighting their fluorescent ligand tools for live-cell GPCR assays.   After 40+ years and 250 publications, Dr. Terry Kenakin is launching a new learning space with video courses, AMAs, and practical insights . Get a sneak peek  and sign up for The Kenakin Brief—his free weekly newslette r.   On the industry side, Novo N

Today’s GPCR researchers want multiplexing, miniaturization, and scale. Here’s the toolkit delivering just that and why it matters now.

Celtarys Research Joins Dr. GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. This partnership aims to bring advanced chemical probe strategies to the forefront. The goal is to accelerate receptor-targeted discovery. They will showcase innovative conjugation methods. These methods will provide scientists with direct access to emerging tools and insights. Explore the partnership Multiplexing GPCR Discovery - Sakmar Lab’s Toolkit Goes Publi

Dr. Sakmar reveals how activating GPCR autoantibodies could be driving disease—and how new tools make them detectable.

Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics.

1.       Introduction Dopamine receptors are G-protein-coupled receptors (GPCRs), which have 5 subtypes -D1-5. The dysfunction of these...

Hello Dr.GPCR readers! This is Lucía from the Celtarys Research chemistry team.  For our very first post in this ecosystem, we wanted to...

How one lab’s 30-year GPCR journey became a global resource. Tools, tech, and team science driving GPCR-RAMP discovery.

Hi GPCR Enthusiasts (and Arrestin Aficionados!)   This week at Dr. GPCR, we’re decoding arrestin-driven signaling and spotlighting the tools to match.   Check out our new on-demand course on non-canonical GPCR behaviors and a podcast episode tracing 30 years of GPCR-RAMP discovery. Additionally, new studies reveal how phosphorylation barcodes shape arrestin engagement, a biased NTSR1 modulator targets pain without the need for opioids, and a real-time lipid probe tracks early

GPCR Colleagues & Curiosity-Driven Minds, We’re starting with exciting Dr. GPCR updates: sharpen your skills with our new on-demand course, Techniques for Effective Lead Optimization with Dr. Terry Kenakin, and catch up on cutting-edge insights through our full library of symposia recordings, now available with your Premium Membership.   We’re also spotlighting breakthroughs that challenge dogma and deepen our view of receptor dynamics, from the surprising discovery that β-a

Ben Clements reflects on pacing, imposter syndrome, and a 10x opioid breakthrough, all powered by curiosity and timing.

Ben Clements shares why fun, mentorship, and community are just as critical as experimental design in GPCR research labs.

Hello Sweet GPCR Enthusiasts, This week at Dr. GPCR: a new podcast episode with Dr. Ben Clements, a tour of our official Dr. GPCR Store, and a spotlight on the cryo-EM structure of the sweet taste receptor.   We’re also tracking biased signaling in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics.  Scroll down for the science, the strategy, and the sweet stuff 🍬

Hello GPCR Colleagues and Collaborators, We’re diving into May with serious momentum. This week brings sharp new insights into how minor changes in ligand structure can flip GPCR function, how ACKR3 modulates cardiac lymphatic repair, and how β-arrestins decode GPCR phosphorylation barcodes. Plus, check out the latest Dr. GPCR tools and key moves in the biotech world. Dr. GPCR Updates   We want your feedback - Help shape the future of Dr. GPCR.   Your voice matters. Every ins